Team, Inc. TISI 深 沪
等待开盘 03-26 09:30:00 美东时间
15.5501
+0.030
+0.19%
华盛通- 最 高15.5501
- 今 开15.52
- 成交量 754股
- 最 低 15.5501
- 昨 收 15.52
- 总市值 7108.57万
- 52周最高 24.25
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 12.34
- 委 比 -81.82%
- 总股本 457.14万
- 历史最高 480.90
- 量 比 0.12
- 振 幅 0.00%
- 历史最低 3.5301
- 每 手 1
- 风险率 2.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Blackstone, Bolt Ventures Acquire Indian Cricket Team For $1.78B
Blackstone, Bolt Ventures, Aditya Birla Group, and The Times of India Group acquired the Royal Challengers Bengaluru cricket franchise.
50分钟前
Microsoft, Nvidia Team Up To Build AI-Powered Nuclear Energy Future
Microsoft (MSFT) and Nvidia (NVDA) are using AI to fast-track nuclear power plants. Discover how this partnership and a $500 price target are fueling a 1% stock jump on Wednesday.
03-25 21:15
Cintas Sees FY2026 Adj EPS $4.86-$4.90 vs $4.88 Est; Raises FY2026 Sales Guidance from $11.150B-$11.220B to $11.210B-$11.240B vs $11.205B Est
Mr. Schneider concluded, "On March 10, 2026, Cintas entered into an agreement to acquire UniFirst Corporation. We are excited about the substantial value we expect to create for shareholders and customers through the
03-25 20:35
RPT-BREAKINGVIEWS-Nelson Peltz bare-knuckles a Janus knockout
RPT-BREAKINGVIEWS-Nelson Peltz bare-knuckles a Janus knockout The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Jonathan Guilford NEW YORK, March 24 (Reuters Breakingviews) - Even at 83, Nelson Peltz is pulling no punches. The bare-knuckle investing brawler top
03-25 20:00
Nxera Pharma Refreshes Board While Maintaining Core Leadership Team
Sosei Group ( ($JP:4565) ) has issued an announcement. Nxera Pharma, a Tokyo- a...
03-25 16:24
FAN Communications Confirms Leadership Team and Adds DX Chief
The latest update is out from FAN Communications. Inc. ( ($JP:2461) ). FAN Comm...
03-25 14:22
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Recursion announced that Dr. Vicki Goodman will replace Dr. David Mauro as its Chief Medical Officer. Dr. Goodman brings extensive oncology and clinical development expertise, including roles at Exelixis, Merck, and Bristol Myers Squibb, and experience as an FDA reviewer. Her leadership will support Recursion's clinical pipeline and regulatory milestones. Dr. Mauro will transition out of his role after three years, with Najat Khan expressing grat...
03-25 11:59
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
Philips launches the IntraSight Plus platform, an FDA-cleared and CE-marked interventional cardiology system combining advanced diagnostic and treatment tools to enhance efficiency, precision, and decision-making in minimally invasive coronary procedures. The platform integrates Class IA IVUS and iFR/FFR physiology, offering streamlined workflows with up to 47% system operation time savings. It enables clinicians to perform comprehensive PCI with...
03-25 09:00
Victory Capital withdraws proposal to acquire Janus Henderson
Victory Capital Management (VCTR) withdrew its proposal to acquire Janus Henderson Group (JHG), Victory said on Tuesday, after Trian and General Capital sweetened their bid for the asset manager. Th...
03-25 04:32
Trian & General Catalyst raise Janus offer to $52.00/shr
Trian & General Catalyst amended their agreement to purchase Janus Henderson (JHG) to $52 a share. Shares of Janus Henderson rose 3.3% in pre-market trading. The latest agreement represents a $3/shr i...
03-24 21:29
